Have a personal or library account? Click to login
Comparative bioavailability of two oral formulations of clopidogrel: Determination of clopidogrel and its carboxylic acid metabolite (SR26334) under fasting and fed conditions in healthy subjects Cover

Comparative bioavailability of two oral formulations of clopidogrel: Determination of clopidogrel and its carboxylic acid metabolite (SR26334) under fasting and fed conditions in healthy subjects

Open Access
|Mar 2014

Abstract

Two randomized, single dose, 2-period, 2-sequence crossover studies were conducted to evaluate the comparative bioavailability of two clopidogrel formulations under fasting and fed conditions. Assessment of bioequivalence was based upon measurement of plasma concentrations of the parent drug, clopidogrel, and its major (inactive) metabolite, clopidogrel carboxylic acid, using improved methanol-free extraction. Bioequivalence of Krka’s formulation to the innovator’s formulation was demonstrated under both fasting and fed conditions on 205 volunteers. Confidence intervals for AUC0-t, AUC0-inf and Cmax of clopidogrel and its main metabolite were well within the acceptance range of 80.00 to 125.00 %. Food substantially increased the bioavailability of clopidogrel from both formulations, while no effect of food on the extent and rate of exposure to the metabolite was observed. The effect of food was comparable between the two formulations, as indicated by the same direction and rank of food impact on the bioavailability of both formulations.

DOI: https://doi.org/10.2478/acph-2014-0001 | Journal eISSN: 1846-9558 | Journal ISSN: 1330-0075
Language: English
Page range: 45 - 62
Published on: Mar 25, 2014
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Related subjects:

© 2014 Nina Brvar, Sylvain Lachance, Ann Lévesque, Marjanca Breznik, Lea Cvitkovič Marčič, Mateja Merslavič, Iztok Grabnar, Tatjana Mateovič-Rojnik, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons License.